SCHEMBL480536

SCHEMBL480536

COC(=O)c1ccc(F)cc1-c1ccc(C(C)C(O)(c2ccc(OC)nc2)C(F)(F)F)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 3/20 0.37
SCN9A Q15858 3/20 0.36
PRKAG1 P54619 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
TDO2 P48775 1/20 0.35
PTGES O14684 2/20 0.34
KDR P35968 1/20 0.34
CTSA P10619 1/20 0.34
NR3C1 P04150 2/20 0.33
PDK2 Q15119 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
PABPC1 P11940 1/20 0.33
KMT2A Q03164 1/20 0.33
GCK P35557 1/20 0.33
OXTR P30559 1/20 0.33
AVPR1A P37288 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480821 0.92 BDKRB1 (0.43) BDKRB1PRKAG1PRKAA1PRKAB1NR3C1
SCHEMBL752294 0.90 PDK2 (0.40) PRKAG1PRKAA1PRKAB1PTGESKDR
SCHEMBL479723 0.90 PDK2 (0.40) PRKAG1PRKAA1PRKAB1PTGESKDR
SCHEMBL755595 0.89 SCN9A (0.37) BDKRB1SCN9APRKAG1PRKAA1PRKAB1
SCHEMBL479973 0.89 SCN9A (0.37) BDKRB1SCN9APRKAG1PRKAA1PRKAB1
SCHEMBL27830963 0.83 PRKAG1 (0.39) SCN9APRKAG1PRKAA1PRKAB1PTGES
SCHEMBL480713 0.81 JMJD6 (0.38) BDKRB1PTGESMEN1KMT2A
SCHEMBL15789889 0.80 NR3C1 (0.37) SCN9APTGESKDRNR3C1MEN1
SCHEMBL15789940 0.80 NR3C1 (0.40) PRKAG1PRKAA1PRKAB1PTGESKDR
SCHEMBL755599 0.80 CYP4F2 (0.36) PTGESMEN1KMT2AOXTRAVPR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411361-B1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-06-18 EP disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2411361-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 BDKRB1 176/4885SCN9A 2134/4885PRKAG1 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.